

Your Request:

Please find below a freedom of information request relating to the diagnosis and treatment of non-small cell lung cancer.

Question 1

Does NHS Cheshire and Merseyside ICB have any local treatment guidelines/pathways/protocols/algorithms for the treatment of non-small cell lung cancer?	Yes	No
	<i>If Yes please provide a copy.</i>	

Our Response:

1) No*.

Your Request:

Question 2

Does NHS Cheshire and Merseyside ICB have protocols for the use of the following targeted drug therapies in the treatment of non-small cell lung cancer?		
Sotorasib (Lumykras)	Yes	No
	<i>If yes please see question 3</i>	
Entrectinib (Rozlytrek)	Yes	No
Larotrectinib (Vitrakvi)	Yes	No
Dabrafenib (Tafinlar)	Yes	No
Trametinib (Mekinist)	Yes	No
Capmatinib (Tabrecta)	Yes	No
Tepotinib (Tepmetko)	Yes	No
Bevacizumab (Avastin)	Yes	No
Ramucirumab (Cyramza)	Yes	No
Atezolizumab (Tecentriq)	Yes	No
Durvalumab (Imfinzi)	Yes	No
Cemiplimab- (Libtayo)	Yes	No
Nivolumab (Opdivo)	Yes	No
Pembrolizumab (Keytruda)	Yes	No
Ipilimumab (Yervoy)	Yes	No
Afatinib (Giotrif)	Yes	No
Dacomitinib (Vizimpro)	Yes	No
Erlotinib (Tarceva)	Yes	No

Gefitinib (Iressa)	Yes	No
Osimertinib (Tagrisso)	Yes	No
Amivantamab (Rybrevant)	Yes	No
Mobocertinib (Exkivity)	Yes	No
trastuzumab deruxtecan (Enhertu)	Yes	No
Alectinib (Alecensa)	Yes	No
Brigatinib (Alunbrig)	Yes	No
Ceritinib (Zykadia)	Yes	No
Crizotinib (Xalkori)	Yes	No
Lorlatinib (Lorviqua)	Yes	No
Entrectinib (Rozlytrek)	Yes	No
Pralsetinib (Gavreto)	Yes	No
Selpercatinib (Retsevmo)	Yes	No
Nintedanib (Vargatef®)	Yes	No

Our Response:

2) Please note from 01 July 2022, Clinical Commissioning Groups (CCGs) were disestablished, and their statutory functions and responsibilities inherited by NHS Cheshire and Merseyside ICB. As a result, NHS Cheshire & Merseyside ICB has inherited the two former formularies in operation by the former CCGs, which are the Pan Mersey Formulary and the Cheshire Formulary.

Information relating to the prescribing status/protocols for the above listed drug therapies (where detailed) can be found using the search function on the formulary websites, which are listed below:

- Cheshire Formulary
www.cheshireformulary.nhs.uk
- Pan Mersey Formulary
www.panmerseyapc.nhs.uk

Your Request:

Question 3

If a local protocol for the use of Sotorasib (Lumykras) for the treatment of non-small cell lung cancer is available please could a copy be provided?

Our Response:

3) NHS Cheshire & Merseyside ICB does not have a local protocol specifically for the use of Sotorasib (Lumykras) for the treatment of non-small cell lung cancer*.

Your Request:

Question 4

Does NHS Cheshire and Merseyside ICB have any local pathways/protocols/guidelines for the use of molecular biomarker testing in diagnosis/treatment of non-small cell lung cancer?	Yes	No
	<i>If yes please provide a copy</i>	

Our Response:

4) NHS Cheshire & Merseyside ICB does not have a local pathways, protocols or guidelines specifically for the use of molecular biomarker testing in diagnosis/treatment of non-small cell lung cancer*.

Your Request:

Question 5

Is NHS Cheshire and Merseyside ICB part of a Cancer alliance or network, if so which ones?

Our Response:

5) Yes, Cheshire & Merseyside Cancer Alliance.

*You may wish to redirect your request for this information to the Cheshire & Merseyside Cancer Alliance, whose contact details are listed on NHS England's website via the following link: <https://www.england.nhs.uk/cancer/cancer-alliances-improving-care-locally/cancer-alliance-contacts/#n6>